Novavax seeks FDA approval for updated Covid-19 vaccine
Pharmaceutical Technology
JUNE 17, 2024
1 version of its Covid-19 vaccine, NVX-CoV2705, for individuals aged 12 years and above. Novavax has sought US FDA approval for an updated JN.1
Vaccine Related Topics 
AstraZeneca to withdraw Covid-19 vaccine globally
Pharmaceutical Technology
MAY 8, 2024
AstraZeneca has begun the global withdrawal of its Covid-19 vaccine Vaxzevria, citing a surplus of updated vaccines.
Vaccination 
299
299 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Novavax seeks EMA approval for updated JN.1 Covid-19 vaccine
Pharmaceutical Technology
JUNE 25, 2024
1 Covid-19 vaccine, NVX-CoV2705, for people aged 12 years and above. Novavax has sought EMA approval for its updated JN.1
Vaccination 321
321 
FDA approves Moderna’s RSV vaccine mRESVIA
Pharmaceutical Technology
JUNE 3, 2024
Moderna has secured approval from the US Food and Drug Administration (FDA) for mRESVIA (respiratory syncytial virus vaccine).
FDA Approval 246
246 
Mandatory COVID Vaccination Policy Template
Advertiser: Aggregage
New vaccine mandates and testing policies will affect employers with more than 100 workers. Get Paycor’s free, customizable vaccination policy template to communicate critical details and new requirements to your employees. Get Paycor’s Template today!
Mankind Pharma acquires Bharat Serums and Vaccines for $1.6bn
Pharmaceutical Technology
JULY 26, 2024
Mankind Pharma has announced a definitive agreement for the acquisition of Bharat Serums and Vaccines (BSV) for Rs136.3bn ($1.6bn).
Vaccination 147
147 
MHRA approves Pfizer-BioNTech’s Comirnaty JN.1 vaccine
Pharmaceutical Technology
JULY 25, 2024
The UK MHRA has authorised Pfizer-BioNTech’s adapted Comirnaty vaccine against the JN.1 1 Covid-19 subvariant for adults and children.
Vaccination 147
147 
AstraZeneca admits Covid-19 vaccine may cause blood clots in “very rare” cases
Pharmaceutical Technology
MAY 1, 2024
AstraZeneca has maintained that while the vaccine may, in “very rare” cases, cause TTS, the casual mechanism for this effect remains unknown.
Vaccination 364
364 
GSK raises forecasts on strong vaccine, HIV drug sales
Bio Pharma Dive
MAY 1, 2024
Sales of the shingles vaccine Shingrix and the RSV shot Arexvy helped fuel quarterly revenue totals that surpassed analyst expectations, though the company warned momentum could slow in the months ahead.
Sales 286
286 
WestGene wins FDA approval for mRNA vaccine to treat certain cancers
Pharmaceutical Technology
MAY 10, 2024
The FDA approved WestGene’s mRNA therapeutic cancer vaccine as mRNA cancer vaccine development rises in popularity.
FDA Approval 279
279 
MHRA agrees licence change for Pfizer-BioNTech’s Comirnaty vaccine
Pharmaceutical Technology
FEBRUARY 12, 2024
vaccine targeting Omicron variant. The UK MHRA has granted approval for a variation in licence of Pfizer-BioNTech’s Comirnaty XBB.1.5
Vaccination 357
357 
Moderna leads the development of mRNA vaccines in infectious diseases
Pharmaceutical Technology
JANUARY 29, 2024
The rapid sequencing of the SARS-CoV-2 and the subsequent development of mRNA vaccines led to the authorisation of the first of these vaccines in late 2020.
Vaccination 278
278 
CDC panel mulls changes to RSV vaccine recommendation
Bio Pharma Dive
MARCH 1, 2024
The expert committee is discussing whether, for certain older adults, to make a universal recommendation for vaccination, rather than the current policy of “shared decisionmaking.”
Vaccination 282
282 
CureVac cuts jobs, licenses out vaccines to GSK
Bio Pharma Dive
JULY 3, 2024
The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like its cancer vaccines.
Vaccination 169
169 
FDA rejects label expansion for Dynavax’s hepatitis B vaccine
Pharmaceutical Technology
MAY 15, 2024
The US agency rejected the expanded use of Dynavax’s vaccine for adults on haemodialysis, citing insufficient efficacy and safety data.
Vaccination 246
246 
Breaking barriers: Advances and challenges in therapeutic cancer vaccines
Bio Pharma Dive
APRIL 1, 2024
The development of cancer vaccines has provided some hope in the battle against cancer worldwide; however, there are still many challenges to overcome when developing these life-saving treatments.
Vaccination 258
258 
Anixa expands cancer vaccine collaboration with Cleveland Clinic
Pharmaceutical Technology
MAY 9, 2024
Anixa Biosciences has expanded its partnership with Cleveland Clinic to develop additional vaccines for cancers.
Vaccination 246
246 
BioNTech’s RNA vaccine sparks potential in pancreatic cancer
Pharmaceutical Technology
MAY 11, 2023
Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.
RNA 345
345 
SK bioscience’s typhoid vaccine receives WHO prequalification
Pharmaceutical Technology
FEBRUARY 26, 2024
SK bioscience has achieved a significant milestone with its typhoid conjugate vaccine, SKYTyphoid, receiving WHO prequalification.
Vaccination 244
244 
Pfizer wins FDA approval of new meningococcal vaccine
Bio Pharma Dive
OCTOBER 23, 2023
The clearance of the pentavalent shot Penbraya adds to Pfizer’s infectious disease portfolio as it adjusts to slumping COVID-19 vaccine sales.
FDA Approval 306
306 
Breakthrough Vaccine Shows High Protection Against Drug-Resistant Superbug in Mice
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 1, 2024
Scientists have developed a vaccine against a notorious drug-resistant superbug, targeting molecules on its surface that are also found on other bacteria and fungi.
Vaccination 203
203 
BioNTech targets infectious diseases for vaccine development
Pharmaceutical Technology
MARCH 28, 2023
Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%
Vaccination 276
276 
SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine
Pharmaceutical Technology
MAY 30, 2023
SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.
Vaccination 298
298 
Brazil’s ANVISA approves Takeda’s dengue vaccine candidate Qdenga
Pharmaceutical Technology
MARCH 14, 2023
The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years.
Vaccination 286
286 
SIGA scores HHS contract for smallpox vaccine Tpoxx worth $113m
Pharmaceutical Technology
JULY 22, 2024
The company’s Tpoxx vaccine is used to treat orthopoxvirus but is only approved for treating smallpox by the US FDA.
Vaccination 130
130 
Novavax gets a lifeline with Sanofi vaccine pact
Bio Pharma Dive
MAY 10, 2024
Sanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination influenza vaccines.
Vaccination 177
177 
UK MHRA approves Takeda’s dengue vaccine Qdenga
Pharmaceutical Technology
FEBRUARY 7, 2023
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]). The vaccine candidate has been approved for active immunisation against the infection in people from four years of age.
Vaccination 264
264 
Moderna’s mRNA influenza vaccine receives $176m boost
Pharmaceutical Technology
JULY 3, 2024
Moderna has received a grant of $176m through the RRPV Consortium to expedite the development of mRNA-based pandemic influenza vaccines.
Vaccination 130
130 
Ghana becomes first country to approve Oxford’s malaria vaccine
Pharmaceutical Technology
APRIL 14, 2023
Ghana’s Food and Drug Authority (FDA) has approved R21/Matrix-M malaria vaccine in children aged 5 to 36 months, marking the first regulatory clearance for the University of Oxford-developed vaccine in any country in the world. Children between the ages of five and 36 months are at highest risk of death from malaria.
Vaccination 279
279 
Cancer Research UK and CRIS fund lung cancer vaccine research
Pharmaceutical Technology
MARCH 25, 2024
Cancer Research UK and the CRIS Cancer Foundation have awarded a £1.7m ($2.1m) grant for developing the lung cancer vaccine LungVax.
Vaccination 246
246 
Cervical cancer elimination in the UK is within sight with HPV vaccine
Pharmaceutical Technology
MAY 20, 2024
A recent study in England has shown that the HPV vaccine in teenagers reduced the rate of cervical cancer by up to 85%.
Vaccination 244
244 
The FDA awarded a record number of review designations to mRNA vaccines in 2023
Pharmaceutical Technology
JUNE 24, 2024
The success of the Covid-19 messenger ribonucleic acid (mRNA) vaccines highlighted the major advantages of utilising mRNA technology in vaccine development.
Vaccination 147
147 
Conflict means millions of children are missing vaccinations, UN says
Pharmaceutical Technology
JULY 15, 2024
Global vaccine coverage is yet to return to levels seen in 2019, shortly before the Covid-19 pandemic caused immunisation programme disruption.
Vaccination 130
130 
RSV vaccine makers’ shares fall as CDC adjusts shot guidance
Bio Pharma Dive
JUNE 27, 2024
The new guidance more strongly urges vaccination in adults who are older or at higher risk, but removes a prior recommendation for adults aged 60 to 74 years without certain risk factors.
Vaccination 152
152 
CHMP recommends authorisation for Pfizer-BioNTech’s Covid-19 vaccine
Pharmaceutical Technology
JUNE 28, 2024
1-adapted Covid-19 vaccine. The EMA's CHMP has recommended granting marketing authorisation for Pfizer and BioNTech’s Omicron JN.1-adapted
Vaccination 147
147 
Latest WHO Covid-19 vaccine guidance may decrease future demand
Pharmaceutical Technology
APRIL 3, 2023
The World Health Organisation (WHO) has revised its recommendations regarding the use of Covid-19 vaccines following a meeting of the agency’s Strategic Advisory Group of Experts on Immunisation (SAGE). The panel emphasised that the extra booster dose recommendation only pertains to one shot and is not for continued annual booster vaccines.
Vaccination 278
278 
SEC recommends permission to SII for Omicron XBB 1.5 variant Covid-19 vaccine
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 14, 2024
A Subject Expert Committee (SEC), which advices the national drug regulator on approvals and clinical trials related to Covid-19 vaccines, has recommended grant of permission to Serum Institute of India (SII) for Omicron XBB 1.5 The vaccine variant […]
Vaccination 182
182 
China grants EUA to Covid-19 vaccine against XBB descendent lineages
Pharmaceutical Technology
JUNE 9, 2023
5+delta) protein vaccine (Sf9 cell). This marks the world’s first Covid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2. The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University. recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta)
Vaccination 269
269 
Japan grants approval for CSL and Arcturus’ Covid-19 vaccine
Pharmaceutical Technology
NOVEMBER 29, 2023
Japan’s MHLW has approved CSL and Arcturus Therapeutics’ self-amplifying mRNA (sa-mRNA) Covid-19 vaccine, ARCT-154.
Vaccination 312
312 
FDA weighs shift in COVID vaccination strategy
Bio Pharma Dive
JANUARY 23, 2023
Agency scientists are proposing to update COVID shots once a year to match circulating coronavirus strains, as well as simplifying current vaccination regimens.
Vaccination 317
317 
GSK and CureVac restructure mRNA vaccine development deal
Pharmaceutical Technology
JULY 3, 2024
GSK and CureVac have announced the restructuring of their existing partnership into a new licensing agreement for mRNA vaccine candidates.
Vaccination 130
130 
Micron Biomedical receives funds to produce needle-free vaccines
Pharmaceutical Technology
NOVEMBER 17, 2023
in funding from the Bill & Melinda Gates Foundation for the bulk manufacturing of needle-free vaccines. Micron Biomedical has received $23.6m
Vaccination 264
264 
‘Project NextGen’ picks new mRNA, intranasal COVID vaccines for funding
Bio Pharma Dive
OCTOBER 13, 2023
The awards, to biotechs Gritstone, Codagenix and CastleVax, are part of the program’s plan to develop vaccines with broader or longer-lasting benefits.
Vaccination 282
282 
FDA fast tracks MimiVax’s glioblastoma vaccine SurVaxM
Pharmaceutical Technology
OCTOBER 13, 2023
The Phase IIb SurVaxM vaccine study will enrol 265 patients and has an estimated completion date in Q2 2024.
Vaccination 279
279 
Let's personalize your content